Syncope	syncope	O	DISEASE	OTHERS	I
and	and	O	O	O	O
QT	qt	O	O	OTHERS	I
prolongation	prolongation	O	O	OTHERS	I
among	among	O	O	O	O
patients	patients	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
methadone	methadone	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
heroin	heroin	O	DISEASE	OTHERS	I
dependence	dependence	O	DISEASE	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
city	city	O	O	O	O
of	of	O	O	O	O
Copenhagen	copenhagen	O	O	O	O
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
Methadone	methadone	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
prescribed	prescribed	O	O	O	O
to	to	O	O	O	O
heroin	heroin	O	O	OTHERS	I
addicts	addicts	O	O	O	O
to	to	O	O	O	O
decrease	decrease	O	O	O	O
illicit	illicit	O	O	O	O
opioid	opioid	O	O	O	O
use	use	O	O	O	O
.	.	O	O	O	O

Prolongation	prolongation	O	O	OTHERS	I
of	of	O	O	OTHERS	I
the	the	O	O	OTHERS	I
QT	qt	O	O	OTHERS	I
interval	interval	O	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
ECG	ecg	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
torsade	torsade	O	DISEASE	OTHERS	I
de	de	O	DISEASE	OTHERS	I
pointes	pointes	O	DISEASE	OTHERS	I
(	(	O	O	O	O
TdP	tdp	O	DISEASE	OTHERS	I
)	)	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
reported	reported	O	O	O	O
in	in	O	O	O	O
methadone	methadone	CHEMICALS	O	OTHERS	I
users	users	O	O	O	O
.	.	O	O	O	O

As	as	O	O	O	O
heroin	heroin	O	O	OTHERS	I
addicts	addicts	O	O	O	O
sometimes	sometimes	O	O	O	O
faint	faint	O	O	O	O
while	while	O	O	O	O
using	using	O	O	O	O
illicit	illicit	O	O	O	O
drugs	drugs	O	O	O	O
,	,	O	O	O	O
doctors	doctors	O	O	O	O
might	might	O	O	O	O
attribute	attribute	O	O	O	O
too	too	O	O	O	O
many	many	O	O	O	O
episodes	episodes	O	O	O	O
of	of	O	O	O	O
syncope	syncope	O	DISEASE	OTHERS	I
to	to	O	O	O	O
illicit	illicit	O	O	O	O
drug	drug	O	O	O	O
use	use	O	O	O	O
and	and	O	O	O	O
thereby	thereby	O	O	O	O
underestimate	underestimate	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
TdP	tdp	O	DISEASE	OTHERS	I
in	in	O	O	O	O
this	this	O	O	O	O
special	special	O	O	O	O
population	population	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
high	high	O	O	O	O
mortality	mortality	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
population	population	O	O	O	O
may	may	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
part	part	O	O	O	O
,	,	O	O	O	O
be	be	O	O	O	O
caused	caused	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
proarrhythmic	proarrhythmic	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
methadone	methadone	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
In	in	O	O	O	O
this	this	O	O	O	O
cross-sectional	cross-sectional	O	O	O	O
study	study	O	O	O	O
interview	interview	O	O	O	O
,	,	O	O	O	O
ECGs	ecgs	O	O	O	O
and	and	O	O	O	O
blood	blood	O	O	O	O
samples	samples	O	O	O	O
were	were	O	O	O	O
collected	collected	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
population	population	O	O	O	O
of	of	O	O	O	O
adult	adult	O	O	O	O
heroin	heroin	O	O	OTHERS	I
addicts	addicts	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
methadone	methadone	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
buprenorphine	buprenorphine	O	O	OTHERS	I
on	on	O	O	O	O
a	a	O	O	O	O
daily	daily	O	O	O	O
basis	basis	O	O	O	O
.	.	O	O	O	O

Of	of	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
Drug	drug	O	O	O	O
Addiction	addiction	O	O	O	O
Service	service	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
municipal	municipal	O	O	O	O
of	of	O	O	O	O
Copenhagen	copenhagen	O	O	O	O
,	,	O	O	O	O
450	450	O	O	O	O
(	(	O	O	O	O
approximately	approximately	O	O	O	O
52	52	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
were	were	O	O	O	O
included	included	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
QT	qt	O	O	O	O
interval	interval	O	O	O	O
was	was	O	O	O	O
estimated	estimated	O	O	O	O
from	from	O	O	O	O
12	12	O	O	O	O
lead	lead	O	O	OTHERS	I
ECGs	ecgs	O	O	O	O
.	.	O	O	O	O

All	all	O	O	O	O
participants	participants	O	O	O	O
were	were	O	O	O	O
interviewed	interviewed	O	O	O	O
about	about	O	O	O	O
any	any	O	O	O	O
experience	experience	O	O	O	O
of	of	O	O	O	O
syncope	syncope	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
association	association	O	O	O	O
between	between	O	O	O	O
opioid	opioid	O	O	O	O
dose	dose	O	O	O	O
and	and	O	O	O	O
QT	qt	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
methadone	methadone	CHEMICALS	O	OTHERS	I
dose	dose	O	O	O	O
and	and	O	O	O	O
reporting	reporting	O	O	O	O
of	of	O	O	O	O
syncope	syncope	O	DISEASE	OTHERS	I
was	was	O	O	O	O
assessed	assessed	O	O	O	O
using	using	O	O	O	O
multivariate	multivariate	O	O	O	O
linear	linear	O	O	O	O
regression	regression	O	O	O	O
and	and	O	O	O	O
logistic	logistic	O	O	O	O
regression	regression	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Methadone	methadone	CHEMICALS	O	OTHERS	I
dose	dose	O	O	O	O
was	was	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
longer	longer	O	O	O	O
QT	qt	O	O	O	O
interval	interval	O	O	O	O
of	of	O	O	O	O
0.140	0.140	O	O	O	O
ms/mg	ms/mg	O	O	O	O
(	(	O	O	O	O
p	p	O	O	OTHERS	I
=	=	O	O	O	O
0.002	0.002	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

No	no	O	O	O	O
association	association	O	O	O	O
between	between	O	O	O	O
buprenorphine	buprenorphine	O	O	OTHERS	I
and	and	O	O	O	O
QTc	qtc	O	O	O	O
was	was	O	O	O	O
found	found	O	O	O	O
.	.	O	O	O	O

Among	among	O	O	O	O
the	the	O	O	O	O
subjects	subjects	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
methadone	methadone	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
28	28	O	O	O	O
%	%	O	O	O	O
men	men	O	O	O	O
and	and	O	O	O	O
32	32	O	O	O	O
%	%	O	O	O	O
women	women	O	O	O	O
had	had	O	O	O	O
prolonged	prolonged	O	O	OTHERS	I
QTc	qtc	O	O	OTHERS	I
interval	interval	O	O	OTHERS	I
.	.	O	O	O	O

None	none	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
subjects	subjects	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
buprenorphine	buprenorphine	O	O	OTHERS	I
had	had	O	O	O	O
QTc	qtc	O	O	O	O
interval	interval	O	O	O	O
>	>	O	O	O	O
0.440	0.440	O	O	O	O
s((1/2	s((1/2	O	O	O	O
)	)	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
50	50	O	O	O	O
mg	mg	O	O	OTHERS	I
higher	higher	O	O	O	O
methadone	methadone	CHEMICALS	O	OTHERS	I
dose	dose	O	O	O	O
was	was	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
1.2	1.2	O	O	O	O
(	(	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
1.1	1.1	O	O	O	O
to	to	O	O	O	O
1.4	1.4	O	O	O	O
)	)	O	O	O	O
times	times	O	O	O	O
higher	higher	O	O	O	O
odds	odds	O	O	O	O
for	for	O	O	O	O
syncope	syncope	O	DISEASE	OTHERS	I
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
Methadone	methadone	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
QT	qt	O	O	OTHERS	I
prolongation	prolongation	O	O	OTHERS	I
and	and	O	O	O	O
higher	higher	O	O	O	O
reporting	reporting	O	O	O	O
of	of	O	O	O	O
syncope	syncope	O	DISEASE	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
population	population	O	O	O	O
of	of	O	O	O	O
heroin	heroin	O	O	OTHERS	I
addicts	addicts	O	O	O	O
.	.	O	O	O	O

